DISCOUNT ZERTIFIKAT - ROCHE GS Share Price

Certificat

DE000VU9B9R3

Delayed Deutsche Boerse AG 18:44:10 24/06/2024 BST
226.1 EUR -0.08% Intraday chart for DISCOUNT ZERTIFIKAT - ROCHE GS
Current month+4.68%
1 month+6.07%
Date Price Change
24/06/24 226.1 -0.08%
21/06/24 226.3 -0.07%
20/06/24 226.4 -0.30%
19/06/24 227.1 +0.11%
18/06/24 226.9 +0.79%

Delayed Quote Deutsche Boerse AG

Last update June 24, 2024 at 06:44 pm

More quotes

Static data

Product typeCertificados de Descuento
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU9B9R
ISINDE000VU9B9R3
Date issued 07/07/2023
Maturity 20/12/2024 (179 Days)
Parity 1 : 1
Emission price 212.4
Emission volume N/A
Settlement Ambos
Currency EUR

Technical Indicators

Highest since issue 227.2
Lowest since issue 209.9
Spread 1.87
Spread %0.82%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
255.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+8.87%
Consensus